More recently, progress in genetics of AML has discovered several recurrent mutations in the remaining 45% of patients with AML, with being prognostic factors (i.e., NPM1, FLT3, IDH1/2, KIT, BCL-2, TP53, and MDM2) [8-13]. The gene discussed is FLT3; the disease is acute myeloid leukemia.